Figure 6.

Unadjusted healthcare costs by service category measured per patient per month among metastatic non-small-cell lung cancer epidermal growth factor receptor activating mutation patients with and without disease progression within 12 months after first-line initiation on an epidermal growth factor receptor tyrosine kinase inhibitor.

EGFRm: Epidermal growth factor receptor activating mutation; mNSCLC: Metastatic non-small-cell lung cancer; PPPM: Per patient per month; TKI: Tyrosine kinase inhibitor.